Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAR-T In Medicare: Add-On Payments But No New Bundle Planned For 2019

Executive Summary

CMS determines in final hospital inpatient rule that it will reimburse CAR-T drugs under an existing Medicare payment bundle supplemented by add-on payments.

You may also be interested in...



Medicare Weighing Higher Add-On Payments For New Drugs, Including CAR-T

Change would increase maximum new technology add-on payments from 50% to 65% of costs.

The Case For CAR-T Grows As Responses Hold Up Longer Term

Novartis and Gilead longer-term data show largely steady response and survival rates, shoring up the clinical and commercial case for their products and justifying continued investment in T-cell therapies. The CAR-T pioneers discuss their progress, including with allogeneic platforms, with Scrip at ASH.

CAR-T Label Update Could Address Medicare Coverage Challenges, FDA’s Gottlieb Suggests

Medicare’s current approach to inpatient CAR-T reimbursement in 2019 would lead to an $186,500 shortfall for providers per patient, stakeholders estimate.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123627

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel